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weeks (5-31). Plasma pharmacokinetic analyses and pharmacodynamic 
analyses on buccal swabs are being performed.
The recommended phase II doses are ABT-751 125 mg twice daily for 
7 days and carboplatin AUC 6 on a 21-day cycle. This regimen is well 
tolerated and shows preliminary evidence of activity for previously 
treated NSCLC.
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Background: Docetaxel has been shown to improve overall survival in 
patients with recurrent NSCLC. Pre-clinical data suggests synergistic 
activity with the combination of docetaxel and imatinib. Paul Matthew, 
et al demonstrated the safety of this combination in the MD Anderson 
trial “Targeting the platelet-derived growth factor receptor in androgen-
independent prostate cancer.” Therefore this combination was admin-
istered to patients with recurrent NSCLC to determine overall response 
rate. 
Methods: This is a phase II study of the combination of Taxotere and 
Gleevec in refractory NSCLC to determine tumor activity, toxicity and 
recommendations for further studies of this combination. Patients must 
have received at least one prior regimen and experienced recurrence or 
have been refractory to the initial treatment. Taxotere was administered 
at 30 mg/M2 on a weekly schedule for 3 weeks followed by one week 
rest. Gleevec was administered at a starting dose of 600 mg daily. Dose 
modiﬁcations to address toxicity were built in to the protocol. 
Results: To date, a total of 10 patients have been enrolled on this study. 
Seven male and 3 female with a median age of 66 years (range 58 - 74). 
A total of 26 cycles were delivered to 10 patients (mean = 3).
Four patients experienced fatal adverse events while on study. Two 
with a non-study related fatal MI (both with history of heart disease). 
One patient developed GI perforation not related to study (history 
of ischemic bowel disease). One patient suffered a fatal pulmonary 
embolus not related to study (history of CAD and peripheral vascular 
disease).
Grade 4 toxicities included periorbital edema (1 pt), pneumonia (2 
pts), diarrhea (1 pt), dehydration (1 pt), dyspnea (1pt), anorexia (1 pt), 
bilateral pleural effusion (1 pt), and neutropenia (2 pts). 
Grade 3 toxicities included hyponatremia, renal failure, hypotension, 
mental status changes, anorexia, azotemia, dyspnea, herpetic esopha-
geal ulcer, pneumonia, cough, neutropenia, shortness of breath, weak-
ness, fatigue, and anemia. 
Results: Responses were minimal. Four of 10 patients received only 
1 cycle. Three of those 4 suffered a fatal adverse event and tumor as-
sessment was not performed. The fourth developed herpetic esophageal 
lesions and was started on 2nd line therapy prior to tumor assessment. 
One patient had stable disease after 2 cycles but progressed after cycle 
3. One patient received 3 cycles, had stable disease after cycle 2 but 
refused additional therapy after cycle 3 due to grade 2 nausea. One 
patient had stable disease after 6 cycles then experienced a fatal pulmo-
nary embolus. An additional patient had a partial response after cycle 4 
but CT after cycle 6 demonstrated progression. Two patients progressed 
after cycle 2. 
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Background: ABT-751 is an orally bioavailable sulfonamide that 
binds to the colchicine site on β-tubulin and inhibits polymerization of 
microtubules. Docetaxel (Taxotere®) is an antineoplastic taxoid. Both 
compounds have been evaluated individually in advanced NSCLC 
subjects and in combination in preclinical xenograft models.
Methods: The Phase 1 open-label dose escalation portion of the study 
was designed to determine the maximum tolerated dose (MTD) and 
recommended Phase 2 dose (RPTD) of ABT-751 when administered 
with docetaxel. For each cycle, subjects received 75 mg/m2 docetaxel 
IV on Day 1 and ABT-751 orally QD for 14 consecutive days fol-
lowed by 7 days off drug. Dose levels of ABT-751 began at 200 mg 
and will escalate by 50 mg increments. Pharmacokinetic sampling was 
performed on Day 1 of Cycle 1. The Phase 2 portion of the study was 
designed to determine the effect of ABT-751 plus docetaxel on progres-
sion-free survival. 
Results: The RPTD was determined to be 200 mg of ABT 751 QD for 
14 days. To date, 7 subjects have been accrued into the Phase 1 portion 
of the study, and preliminary safety data are available for 5. One of the 
subjects in the 200 mg cohort experienced a dose-limiting toxicity of 
grade 4 thrombocytopenia. Two subjects experienced an adverse event 
(1 multiple sclerosis and 1 hiccups) rated grade 3 using the Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0. No 
grade 4 or 5 adverse events were reported. Preliminary results indicate 
that the pharmacokinetics of ABT-751 and its glucuronide and sulfate 
metabolites after concomitant administration of a single dose of ABT-
751 (200 mg) with docetaxel were comparable to those after a single 
dose of ABT-751 (200 mg) alone in a previous study.
Pharmacokinetic parameters of ABT-751 after a 200 mg oral dose of 
ABT-751
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ABT-751 
Alone#
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ABT-751 
Glucuronide 
Alone#
ABT-751 
Sulfate with 
Docetaxel##
ABT-751 
Sulfate 
Alone#
N 3 23 3 23 3 23
Tmax (h) 2.3 ± 1.5 2.0 ± 1.3 5.0 ± 2.7 4.5 ± 2.2 5.0 ± 2.7 4.0 ± 2.4
Cmax 
(μg/mL) 9.1 ± 5.0 9.1 ± 4.5 6.1 ± 4.3 4.6 ± 1.7 8.0 ± 3.2 7.4 ± 3.2
AUC0-8 
(μg*h/mL) 33.8 ± 15.1 33.0 ± 10.1 30.2 ± 22.5 26.6 ± 10.5 43.6 ± 21.3 39.5 ± 15.0
#Results from Phase 1 Study M01-303 were used as a historical reference.
Conclusions: The RPTD of the combination of ABT-751 and docetaxel 
has been determined. Coadministration of docetaxel with ABT-751 
does not appear to affect the pharmacokinetics of ABT 751.
